Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy

MLA

David García‐Bernal, et al. “Endothelial Dysfunction and Its Critical Role in COVID‐19‐associated Coagulopathy: Defibrotide as an Endothelium‐protective, Targeted Therapy.” EJHaem, vol. 2, no. 3, Aug. 2021, pp. 680–81. EBSCOhost, https://doi.org/10.1002/jha2.198.

APA

David García‐Bernal, Edward Richardson, Israel Vlodavsky, Carmelo Carlo‐Stella, Massimo Iacobelli, Rubén Jara, Paul G. Richardson, & Jose M. Moraleda. (2021). Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy. EJHaem, 2(3), 680–681. https://doi.org/10.1002/jha2.198

Chicago

David García‐Bernal, Edward Richardson, Israel Vlodavsky, Carmelo Carlo‐Stella, Massimo Iacobelli, Rubén Jara, Paul G. Richardson, and Jose M. Moraleda. 2021. “Endothelial Dysfunction and Its Critical Role in COVID‐19‐associated Coagulopathy: Defibrotide as an Endothelium‐protective, Targeted Therapy.” EJHaem 2 (3): 680–81. doi:10.1002/jha2.198.